- Gregg Fergus can tell his fellow travelers a thing or two about commuting.
The Madison native has joined Baird Venture Partners
as an executive-in-residence and one of its portfolio companies, Caden Biosciences
, as senior vice president of corporate development.
......Full article >>>
Equity, said Fergus would reinforce Baird's focus on the life-science tools market. He expects Fergus to help Baird's healthcare and life science teams evaluate new investment opportunities, and manage its current portfolio of companies. Baird Private Equity has raised and managed $1.8 billion in capital.
Gregg brings operational experience and perspective that will help us in a number o......Full article >>>
re from 800 to 1,000 GPCRs on the human genome. Of those, roughly 400 are thought to be pharmaceutically relevant, but only 40 have been successfully targeted by commercial drugs - representing $50 billion in annual sales - and many of those drugs have side effects.
Caden Biosciences might be able to partner with a big pharma company to pinpoint the remaining intractable targets, and addr......Full article >>>
Source:wistechnology.com By Joe Vanden Plas 02/19/07Related biology technology :1
. Biotech officials praise focus of new venture fund2
. Gala Biotech among companies sold for $3.3 billion3
. Biotech with Madison ties raises $21M in capital4
. Biotech firm uses live heart tissue in drug screens5
. Biotech talent drew venture-funded firm to Madison6
. Biotech firm has strokes, Alzheimers in its sights7
. 42 days until the 2006 Olympics of Biotechnology in Chicago8
. Biotech crops gaining acceptance, but their full promise has yet to be fulfilled9
. Biotech leads list of top U.S. companies to work for10
. Biotech flourishes in 2005 while Big Pharma is on the decline11
. Though Weakening, Biotech IPO Market Still Viable, Burril & Co. Says